CD274 and non-small cell lung carcinoma: In conclusion, in this economic evaluation comparing the 3 approved first-line therapies for advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective treatment strategy compared to pembrolizumab, and a dominant alternative against atezolizumab.